CASEY ENGLISH: Open Payments
NPI 1780259135 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,946 in 150 payments from 17 companies in 2025. Trend: 2023 $963 · 2024 $2,005 · 2025 $2,946
Food & beverage: $2,493Education: $453
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $410 |
| GENZYME CORPORATION | 16 | $367 |
| Regeneron Healthcare Solutions, Inc. | 9 | $351 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 10 | $332 |
| Janssen Biotech, Inc. | 16 | $313 |
| UCB, Inc. | 13 | $269 |
| Galderma Laboratories, L.P. | 14 | $203 |
| E.R. Squibb & Sons, L.L.C. | 17 | $182 |
| Novartis Pharmaceuticals Corporation | 8 | $137 |
| SANOFI-AVENTIS U.S. LLC | 1 | $99 |
Products named: DUPIXENT, TREMFYA, Bimzelx, RINVOQ, NEMLUVIO, SKYRIZI, Sotyktu, ILUMYA.
Industry payments across TX — which companies pay providers there.
